Literature DB >> 17177964

Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes.

Q-Z Li1, J Zhou, A E Wandstrat, F Carr-Johnson, V Branch, D R Karp, C Mohan, E K Wakeland, N J Olsen.   

Abstract

The objective of this study was to investigate the prevalence and clinical significance of a spectrum of autoantibodies in systemic lupus erythematosus and incomplete lupus syndromes using a proteome microarray bearing 70 autoantigens. Microarrays containing candidate autoantigens or control proteins were printed on 16-section slides. These arrays were used to profile 93 serum samples from patients with systemic lupus erythematosus (SLE (n = 33), incomplete LE (ILE; n = 23), first-degree relatives (FDRs) of SLE patients (n = 20) and non-autoimmune controls (NC; n = 17). Data were analysed using the significance analysis of microarray (SAM) and clustering algorithms. Correlations with disease features were determined. Serum from ILE and SLE patients contained high levels of IgG autoantibodies to 50 autoantigens and IgM autoantibodies to 12 autoantigens. Elevated levels of at least one IgG autoantibody were detected in 26% of SLE and 19% of ILE samples; elevated IgM autoantibodies were present in 13% of SLE and 17% of ILE samples. IgG autoantibodies segregated into seven clusters including two specific for DNA and RNA autoantigens that were correlated with the number of lupus criteria. Three IgG autoantibody clusters specific for collagens, DNA and histones, were correlated with renal involvement. Of the four IgM autoantibody clusters, two were correlated negatively with the number of lupus criteria; none were correlated with renal disease. The IgG : IgM autoantibody ratios generally showed a stepwise increase in the groups following disease burden from NC to SLE. Insights derived from the expanded autoantibody profiling made possible with the antigen array suggest differences in autoreactivity in ILE and SLE. Determining whether the IgM aurotreactivity that predominates in ILE represents an early stage prior to IgG switching or is persistent and relatively protective will require further longitudinal studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17177964      PMCID: PMC1810453          DOI: 10.1111/j.1365-2249.2006.03251.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy.

Authors:  R Cervera; O Viñas; M Ramos-Casals; J Font; M García-Carrasco; A Sisó; F Ramírez; Y Machuca; J Vives; M Ingelmo; R W Burlingame
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

2.  Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays.

Authors:  Quan-Zhen Li; Quan Li Zhen; Chun Xie; Tianfu Wu; Meggan Mackay; Cynthia Aranow; Chaim Putterman; Chandra Mohan
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT).

Authors:  A J Swaak; H van de Brink ; R J Smeenk; K Manger; J R Kalden; S Tosi; A Marchesoni; Z Domljan; B Rozman; D Logar; G Pokorny; L Kovacs; A Kovacs; P G Vlachoyiannopoulos; H M Moutsopoulos; H Chwalinska-Sadowska; B Dratwianka; E Kiss; N Cikes; B Anic; M Schneider; R Fischer; S Bombardieri; M Mosca; W Graninger; J S Smolen
Journal:  Rheumatology (Oxford)       Date:  2001-01       Impact factor: 7.580

4.  Autoantibodies within families of patients with systemic lupus erythematosus are not directed against the same nuclear antigens.

Authors:  M W van der Linden; R G Westendorp; M Zidane; L Meheus; T W Huizinga
Journal:  J Rheumatol       Date:  2001-02       Impact factor: 4.666

5.  Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus.

Authors:  L M Vilá; A M Mayor; A H Valentín; M García-Soberal; S Vilá
Journal:  Lupus       Date:  2000       Impact factor: 2.911

6.  Autoantigen microarrays for multiplex characterization of autoantibody responses.

Authors:  William H Robinson; Carla DiGennaro; Wolfgang Hueber; Brian B Haab; Makoto Kamachi; Erik J Dean; Sylvie Fournel; Derek Fong; Mark C Genovese; Henry E Neuman de Vegvar; Karl Skriner; David L Hirschberg; Robert I Morris; Sylviane Muller; Ger J Pruijn; Walther J van Venrooij; Josef S Smolen; Patrick O Brown; Lawrence Steinman; Paul J Utz
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

7.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

8.  Outcome of incomplete systemic lupus erythematosus after 10 years.

Authors:  C Ståhl Hallengren; O Nived; G Sturfelt
Journal:  Lupus       Date:  2004       Impact factor: 2.911

9.  Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus.

Authors:  Josefina Cortés-Hernández; Josep Ordi-Ros; Moisés Labrador; Segundo Buján; Eva Balada; Alfons Segarra; Miquel Vilardell-Tarrés
Journal:  Am J Med       Date:  2004-02-01       Impact factor: 4.965

Review 10.  Autoantibody profiling for the study and treatment of autoimmune disease.

Authors:  Wolfgang Hueber; Paul J Utz; Lawrence Steinman; William H Robinson
Journal:  Arthritis Res       Date:  2002-05-07
View more
  105 in total

1.  Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.

Authors:  Shannon K O'Neill; Andrew Getahun; Stephen B Gauld; Kevin T Merrell; Idan Tamir; Mia J Smith; Joseph M Dal Porto; Quan-Zhen Li; John C Cambier
Journal:  Immunity       Date:  2011-11-09       Impact factor: 31.745

2.  Autoantibody profiles in two patients with non-autoimmune muscle disease implicate a role for gliadin autoreactivity.

Authors:  Nancy J Olsen; Heidi Prather; Quan-Zhen Li; Dennis K Burns
Journal:  Neuromuscul Disord       Date:  2010-01-27       Impact factor: 4.296

3.  B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice.

Authors:  Mike Recher; Siobhan O Burns; Miguel A de la Fuente; Stefano Volpi; Carin Dahlberg; Jolan E Walter; Kristin Moffitt; Divij Mathew; Nadine Honke; Philipp A Lang; Laura Patrizi; Hervé Falet; Marton Keszei; Masayuki Mizui; Eva Csizmadia; Fabio Candotti; Kari Nadeau; Gerben Bouma; Ottavia M Delmonte; Francesco Frugoni; Angela B Ferraz Fomin; David Buchbinder; Emma Maria Lundequist; Michel J Massaad; George C Tsokos; John Hartwig; John Manis; Cox Terhorst; Raif S Geha; Scott Snapper; Karl S Lang; Richard Malley; Lisa Westerberg; Adrian J Thrasher; Luigi D Notarangelo
Journal:  Blood       Date:  2012-02-01       Impact factor: 22.113

Review 4.  New tools for classification and monitoring of autoimmune diseases.

Authors:  Holden T Maecker; Tamsin M Lindstrom; William H Robinson; Paul J Utz; Matthew Hale; Scott D Boyd; Shai S Shen-Orr; C Garrison Fathman
Journal:  Nat Rev Rheumatol       Date:  2012-05-31       Impact factor: 20.543

5.  Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia.

Authors:  Elena Crestani; Stefano Volpi; Fabio Candotti; Silvia Giliani; Lucia Dora Notarangelo; Julia Chu; Juan Carlos Aldave Becerra; David Buchbinder; Janet Chou; Raif S Geha; Maria Kanariou; Alejandra King; Cinzia Mazza; Daniele Moratto; Robert Sokolic; Elizabeth Garabedian; Fulvio Porta; Maria Caterina Putti; Rima H Wakim; Erdyni Tsitsikov; Sung-Yun Pai; Luigi D Notarangelo
Journal:  J Allergy Clin Immunol       Date:  2015-09-26       Impact factor: 10.793

Review 6.  Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays.

Authors:  Edwin Liu; George S Eisenbarth
Journal:  Clin Immunol       Date:  2007-09-27       Impact factor: 3.969

7.  Development of SLE among "potential SLE" patients seen in consultation: long-term follow-up.

Authors:  M Al Daabil; E M Massarotti; A Fine; H Tsao; P Ho; P H Schur; B L Bermas; K H Costenbader
Journal:  Int J Clin Pract       Date:  2014-05-23       Impact factor: 2.503

8.  Analysis of IgM antibody production and repertoire in a mouse model of Sjögren's syndrome.

Authors:  Jill M Kramer; Nichol E Holodick; Teresa C Vizconde; Indu Raman; Mei Yan; Quan-Zhen Li; Daniel P Gaile; Thomas L Rothstein
Journal:  J Leukoc Biol       Date:  2015-09-17       Impact factor: 4.962

9.  TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.

Authors:  Tanvi Arkatkar; Holly M Jacobs; Samuel W Du; Quan-Zhen Li; Kelly L Hudkins; Charles E Alpers; David J Rawlings; Shaun W Jackson
Journal:  Kidney Int       Date:  2018-06-12       Impact factor: 10.612

10.  Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes.

Authors:  Q-Z Li; J Zhou; Y Lian; B Zhang; V K Branch; F Carr-Johnson; D R Karp; C Mohan; E K Wakeland; N J Olsen
Journal:  Clin Exp Immunol       Date:  2009-12-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.